Rss Feed

Subscribe to Rss Feed feed
Latest Medical Research News and Research
Updated: 8 min 9 sec ago

Study may lead to new treatment for incurable brain cancer in children

Thu, 04/15/2021 - 10:10
Research by Australian scientists could pave the way to a new treatment for a currently incurable brain cancer in children called Diffuse Intrinsic Pontine Glioma, or DIPG. Affecting about 20 children in Australia each year, DIPG is a devastating disease with an average survival time of just nine months after diagnosis.

New analysis examines impact of breast cancer on African American survivors' marital relationships

Thu, 04/15/2021 - 10:09
Most African American women described successfully navigating the challenges of a breast cancer diagnosis with their partners, finds a new analysis from the Brown School at Washington University in St. Louis.

New genetic markers may lead to personalized treatments for lung cancer

Thu, 04/15/2021 - 10:08
Investigators at Wake Forest School of Medicine, part of Wake Forest Baptist Health, have identified a set of new genetic markers that could potentially lead to new personalized treatments for lung cancer.

Malaria mutations may be gaining a foothold in Africa, shows new data

Thu, 04/15/2021 - 10:06
New data provide the first clinical evidence that drug-resistant mutations in the malaria parasite Plasmodium falciparum may be gaining a foothold in Africa.

Researchers identify long-sought enzyme that prevents cancer

Thu, 04/15/2021 - 09:20
Researchers have found a long-sought enzyme that prevents cancer by enabling the breakdown of proteins that drive cell growth, and that causes cancer when disabled.

Pigs’ brain size and digestive system are excellent analogs for human newborns

Thu, 04/15/2021 - 09:13
Before humans can benefit from new drug therapies and nutritional additives, scientists test their safety and efficacy in animals, typically mice and rats.

Phase 3 trial finds corticosteroid inhaler speeds recovery time in COVID-19 patients

Thu, 04/15/2021 - 09:07
The corticosteroid budesonide shows promise in treating patients with mild COVID-19 infection. Interim analysis of the phase 3 PRINCIPLE clinical trial was posted to the medRxiv preprint server. Researchers found a 3-day faster recovery of COVID-19 symptoms in people at high risk for severe side effects administered a budesonide inhaler. There was also a 2.1% reduction in hospitalization and death.

Updated Moderna vaccines neutralize South African SARS-CoV-2 variant in mice

Thu, 04/15/2021 - 08:22
Researchers in the United States have conducted a pre-clinical study demonstrating the efficacy of two updated versions of the Moderna mRNA-1273 vaccine against variants of severe acute respiratory syndrome coronavirus 2 – the agent that causes coronavirus disease 2019 (COVID-19).

Study sheds light on reduced neutralization of SARS-CoV-2 variants of concern

Thu, 04/15/2021 - 07:59
Researchers in the United States have predicted the binding epitopes of uncharacterized neutralizing antibodies that target the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein.

Early monoclonal antibody therapies beneficial for COVID-19, finds study

Wed, 04/14/2021 - 17:19
A team of scientists recently conducted a large-scale study at Northwell Health, New York, USA, to evaluate the efficacy of neutralizing monoclonal antibody (MAB) therapies in preventing disease progression among patients with mild to moderate COVID-19. The findings reveal that the timing of initiating MAB therapy is a crucial factor in determining its efficacy against COVID-19.

SARS-CoV-2 mutations impact T-cell recognition of virus

Wed, 04/14/2021 - 11:58
A new research paper posted to the bioRxiv preprint server deals with the impact of these mutations on adaptive cellular immunity.

A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity

Wed, 04/14/2021 - 11:39
As newer vaccines are being developed to combat the ongoing pandemic of coronavirus disease 2019 (COVID-19), targeting the pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new preprint research paper posted to the bioRxiv server describes a new subunit nanovaccine that appears to have robust immunogenicity and neutralizing activity.

Study demonstrates that the main creators of SARS-CoV-2 mutations are vaccine-suppressed

Wed, 04/14/2021 - 11:18
A new research paper posted to the medRxiv* preprint server describes the changes in genomic sequence observed during the course of infection in a patient on the drug tacrolimus, along with steroids, both potent immunosuppressants, and who also received convalescent plasma treatment. These mutations were observed to occur within three weeks from infection.

Ponatinib identified as a potent inhibitor of SARS-CoV2-induced cytokine storm

Wed, 04/14/2021 - 10:51
Researchers at the Human Biology Division, Fred Hutchinson Cancer Research Center in Washington, United States, found that the FDA-approved, multi-kinase inhibitor Ponatinib is a potent inhibitor of the N-terminal domain (NTD) -mediated cytokine storm. Ponatinib is an oral drug used for the treatment of chronic myeloid leukemia (CML).

No evidence B.1.1.7. variant worsens symptoms or increases risk of long COVID

Wed, 04/14/2021 - 10:14
The study, published in The Lancet, demonstrates that there is no evidence of a link between severe illness and death and lineage when comparing the B.1.1.7 lineage and other variants.

Risk of E.R. visit or hospitalization 82% lower in mAbs-treated SARS-CoV-2 patients: Study

Wed, 04/14/2021 - 09:42
Recently, researchers from the U.S. reviewed electronic health records of SARS-CoV-2 patients at a medical center that started mAb infusions in January 2021 with the support of the National Disaster Medical System, part of the U.S. Department of Health and Human Services. The study is published on the preprint server, medRxiv.

Study offers a non-invasive avenue for monitoring buildings for COVID-19 outbreaks

Wed, 04/14/2021 - 09:15
A study done in rooms where COVID-19 patients were isolated shows that the virus's RNA - part of the genetic material inside a virus - can persist up to a month in dust.

Experimental evidence that ADAM17 inhibition prevents severe COVID-19

Wed, 04/14/2021 - 09:06
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive-sense single-stranded RNA virus that is contagious in humans. It is the causal agent of the ongoing coronavirus 2019 (COVID-19) pandemic. This virus causes a mild to severe infection and has claimed over 2.95 million lives worldwide. SARS-CoV-2 is the successor to SARS-CoV-1, the virus that caused the 2002–2004 SARS outbreak.

Studies provide insights into characteristics and clinical effect of SARS-CoV-2 B.1.1.7 variant

Wed, 04/14/2021 - 08:57
Two new studies, published in The Lancet Infectious Diseases and The Lancet Public Health, found no evidence that people with the B.1.1.7. variant experience worse symptoms or a heightened risk of developing long COVID compared with those infected with a different COVID-19 strain.

Researchers develop model for SARS-CoV-2 fusion intermediate that helps membrane fusion

Wed, 04/14/2021 - 08:23
The spike protein is the main part of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the infection. It consists of two subunits S1 and S2. Upon entry of the virus into the human body, the S1 subunit helps the virus bind to the angiotensin-converting enzyme 2 (ACE2) receptors on host cells.